Electrocardiographic Effects of a Supratherapeutic Dose of <scp>WCK</scp> 2349, a Benzoquinolizine Fluoroquinolone

Mason, Jay W.; Chugh, Rakesh; Patel, Anasuya; Gutte, Ranjeet; Bhatia, Ashima

doi:10.1111/cts.12594

Cited by 13 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The excellent oral bioavailability of levonadifloxacin not affected by food, coupled with favourable pharmacokinetic and pharmacodynamics profile makes it a preferred antibiotic for varied infections including anaerobic infections. Non-clinical and clinical studies have established an excellent safety profile of levonadifloxacin with lack of potential adverse effects, such as phototoxicity, prolongation of QT interval, [19] hepatotoxicity, and nephrotoxicity, thus potentially offering a better option for the treatment of bacterial CABP. Levonadifloxacin could be a preferred antibiotic of choice for empirical therapy, which enables the clinician for easy switch-over from injectable to oral therapy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Levonadifloxacin in the Management of Community-Acquired Bacterial Pneumonia (CABP): Findings of a Retrospective, Real-World, Multi-centre Study

Prabhudesai

Jain

Borade

et al. 2021

ijirms

View full text Add to dashboard Cite

Background: Community-acquired bacterial pneumonia (CABP) remains a global public health threat and is a leading cause of hospitalization and infection-linked mortality. Levonadifloxacin is a novel benzoquinolizine antibiotic with a broad-spectrum activity including methicillin-resistant Staphylococcus aureus (MRSA) and CABP-pathogens. Methods: This multi-centre, retrospective, post-marketing, real-world study assessed the efficacy and safety of levonadifloxacin oral and/or intravenous therapy in the treatment of CABP. Data from 338 patients above 17 years-of-age who received levonadifloxacin (oral or intravenous or both) was collected from 89 healthcare facilities across India. Information on clinical condition, comorbidities, complications, and details of concurrent therapy (including antimicrobial agents) was also collected. Study outcomes were clinical and microbial success at the end of therapy while safety was assessed based on clinical and laboratory adverse events. Results: Of the 338 patients, 244 (72.2%) were male, 93 (27.5%) were female and 1 (0.43%) was a transgender. About 294 (87.0%) patients were hospital-treated and 44 (13%) received outpatient treatment. About 248 (73.4%) patients received intravenous levonadifloxacin treatment, 79 (23.4%) received oral and 11 (3.3%) received intravenous followed by oral levonadifloxacin therapy. The common comorbid conditions were diabetes (14.2%) and hypertension (8.6%). Mean duration of levonadifloxacin therapy was 6.4 days. Clinical and microbial success in levonadifloxacin-treated patients was 95.0% (321/388) and 96.8% (150/155), respectively. Conclusions: Levonadifloxacin showed promising clinical outcomes and safety when used as an intravenous and/or oral for the treatment of CABP, both in outpatients as well as hospitalized patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Levonadifloxacin in the Management of Community-Acquired Bacterial Pneumonia (CABP): Findings of a Retrospective, Real-World, Multi-centre Study

Prabhudesai

Jain

Borade

et al. 2021

ijirms

View full text Add to dashboard Cite

show abstract

“…WCK 2349 had no effect on baseline and placebo-corrected QTcF (QT interval adjusted for heart rate using the Fridericia method), QRS, or PR interval. Except for a possibly transient elevation in HR, which appears to be clinically negligible, a supratherapeutic dose of WCK 2349 is not likely to elicit clinically significant ECG effects and thus can provide a viable alternative to QT prolonging antibiotics ( NCT02217930 ) [ 66 ].…”

Section: Meeting the Unmet Need With Levonadifloxacin IV And Oralmentioning

confidence: 99%

Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Mehta

Mishra

Paliwal

et al. 2022

Critical Care Research and Practice

View full text Add to dashboard Cite

Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well as Gram-negative bacteria. Levonadifloxacin has a well-defined mechanism of action involving a strong affinity for DNA gyrase as well as topoisomerase IV. Alalevonadifloxacin with widely differing solubility and oral bioavailability has pharmacokinetic profile identical to levonadifloxacin. Unlike existing MRSA drugs such as vancomycin and linezolid, which cause unfavorable side effects like nephrotoxicity, bone-marrow toxicity, and muscle toxicity, levonadifloxacin/alalevonadifloxacin has demonstrated superior safety and tolerability features with no serious adverse events. Levonadifloxacin/alalevonadifloxacin could be a useful weapon in the battle against infections caused by resistant microorganisms and could be a preferred antibiotic of choice for empirical therapy in the future.

show abstract

“…46,47 WCK 771 when dosed at 800 mg intravenously and its pro-drug (WCK 2349) dosed at 1000mg orally in clinical trials attained a half-life of 6 h, a concentration that when dosed BID systemically has been effective to treat MRSA infections. 48,49…”

Section: Treatment Of the Futurementioning

confidence: 99%

Overview of methicillin resistant Staphylococcus aureus mediated bone and joint infections in India

Prabhoo¹,

Chaddha²,

Iyer³

et al. 2019

Orthop Rev (Pavia)

View full text Add to dashboard Cite

Staphylococcus aureus is the most common pathogen causing bone and joint infections (BJI). In India, prevalence of Methicillin resistant Staphylococcus aureus (MRSA) is increasing at an alarming rate and emerged as an important contributor towards the difficult to treat BJI. Currently available anti-MRSA agents have their own limitations with regards to reduced susceptibility as well as safety and tolerability. Furthermore, biofilms over the prosthesis with invariably multi-drug resistant strains leads to complex treatment processes. This necessitates the need to develop and screen new antibiotics against MRSA that can easily penetrate the deep pockets of infection and take care of the challenges discussed. This review aims to discuss on MRSA infection in bone and joint infection, current antibiotic regimen, its associated limitations, and finally, the need to develop new antibiotic therapy for effective management of patients with BJI.

show abstract

Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone

Cited by 13 publications

References 10 publications

Efficacy and Safety of Levonadifloxacin in the Management of Community-Acquired Bacterial Pneumonia (CABP): Findings of a Retrospective, Real-World, Multi-centre Study

Efficacy and Safety of Levonadifloxacin in the Management of Community-Acquired Bacterial Pneumonia (CABP): Findings of a Retrospective, Real-World, Multi-centre Study

Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Overview of methicillin resistant Staphylococcus aureus mediated bone and joint infections in India

Contact Info

Product

Resources

About